US Stock Insider Trading | Ptc Therapeutics disclosed 1 company insider transaction on March 13

robot
Abstract generation in progress

On March 13, 2026, Ptc Therapeutics (PTCT) disclosed an insider trading transaction. Director Klein Matthew B. sold 2,662 shares on March 12, 2026.

【Recent Insider Transactions】

Disclosure Date Position Name Transaction Date Buy/Sell Quantity Price per Share/USD Total Amount/USD
March 13, 2026 Director Klein Matthew B. March 12, 2026 Sell 2,662 64.08 $170.6k
March 12, 2026 Director Okey Stephanie March 10, 2026 Buy 15.2k 33.63 $510.1k
March 12, 2026 Director Okey Stephanie March 10, 2026 Sell 15.2k 70.00 $1.06M
March 9, 2026 Director Okey Stephanie March 5, 2026 Sell 6,333 63.38 $401.4k
March 9, 2026 Executive Golden Lee Scott March 5, 2026 Sell 10k 63.38 $633.8k
March 9, 2026 Executive Almstead Neil Gregory March 5, 2026 Sell 3,989 63.38 $252.8k
February 23, 2026 Executive Boulding Mark Elliott February 19, 2026 Sell 800 68.54 $54.8k
February 23, 2026 Executive Boulding Mark Elliott February 19, 2026 Sell 2,219 69.82 $154.9k
February 20, 2026 Executive Gravier Pierre February 18, 2026 Sell 2,992 69.36 $207.5k
February 20, 2026 Executive Pauwels Eric February 18, 2026 Sell 3,019 69.36 $209.4k

【Company Information】

Ptc Therapeutics, Inc. was incorporated on March 31, 1998, as a Delaware corporation. PTC Therapeutics is a biopharmaceutical company focused on oral drugs for post-transcriptional control processes, discovering and developing proprietary small-molecule medicines. The company’s research and development plans target multiple therapeutic areas, with a particular focus on developing and commercializing treatments for orphan and ultra-orphan rare diseases. The company’s leading candidate product is ataluren, which is used to treat a genetic disorder caused by a mutation known as nonsense mutation.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin